Related Experiment Video
Updated: Nov 10, 2025

A Purification and In Vitro Activity Assay for a pppGpp Synthetase from Clostridium difficile
Published on: November 3, 2018
A Putative Amidase Endolysin Encoded by Clostridium perfringens St13 Exhibits Specific Lytic Activity and Synergizes
Hiroshi Sekiya1, Maho Okada2, Eiji Tamai1
1Department of Infectious Disease, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan.
Abstract:
Clostridium perfringens is an often-harmful intestinal bacterium that causes various diseases ranging from food poisoning to life-threatening fulminant disease. Potential treatments include phage-derived endolysins, a promising family of alternative antimicrobial agents. We surveyed the genome of the C. perfringens st13 strain and identified an endolysin gene, psa, in the phage remnant region. Psa has an N-terminal catalytic domain that is homologous to the amidase_2 domain, and a C-terminal domain of unknown function. psa and gene derivatives encoding various Psa subdomains were cloned and expressed in Escherichia coli as N-terminal histidine-tagged proteins. Purified His-tagged full-length Psa protein (Psa-his) showed C. perfringens-specific lytic activity in turbidity reduction assays. In addition, we demonstrated that the uncharacterized C-terminal domain has cell wall-binding activity. Furthermore, cell wall-binding measurements showed that Psa binding was highly specific to C. perfringens. These results indicated that Psa is an amidase endolysin that specifically lyses C. perfringens; the enzyme's specificity is highly dependent on the binding of the C-terminal domain. Moreover, Psa was shown to have a synergistic effect with another C. perfringens-specific endolysin, Psm, which is a muramidase that cleaves peptidoglycan at a site distinct from that targeted by Psa. The combination of Psa and Psm may be effective in the treatment and prevention of C. perfringens infections.
Insights
Phage-derived endolysins offer new treatments for Clostridium perfringens infections. The Psa endolysin specifically targets and lyses C. perfringens, showing synergistic effects with Psm for enhanced therapeutic potential.
Area of Science:
- Microbiology
- Bacteriology
- Enzymology
Background:
- Clostridium perfringens causes various intestinal diseases.
- Phage-derived endolysins are promising antimicrobial agents.
- Novel therapeutic strategies are needed to combat C. perfringens infections.
Purpose of the Study:
- To identify and characterize a novel endolysin from C. perfringens.
- To evaluate the lytic activity and specificity of the identified endolysin.
- To explore the potential synergistic effects of the endolysin in combination with other agents.
Main Methods:
- Genome survey of C. perfringens st13 strain to identify endolysin gene psa.
- Cloning and expression of psa and its derivatives in Escherichia coli.
- Purification of His-tagged Psa protein and assessment of lytic activity via turbidity reduction assays.
- Characterization of the C-terminal domain's cell wall-binding activity and specificity.
Main Results:
- Identified and cloned the endolysin gene psa from C. perfringens.
- Purified Psa protein demonstrated specific lytic activity against C. perfringens.
- The C-terminal domain of Psa was found to mediate specific cell wall binding.
- Psa exhibited synergistic lytic activity with the endolysin Psm.
Conclusions:
- Psa is a novel amidase endolysin that specifically lyses Clostridium perfringens.
- The specificity of Psa is primarily determined by its C-terminal domain.
- The combination of Psa and Psm presents a potential strategy for treating and preventing C. perfringens infections.
Related Concept Videos
Lysosomal Hydrolases
Lysosomes
Caspases
Gene Regulation in Microbial Communities: Quorum Sensing

